Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absence, accuracy, al, alleged, alleging, antitrust, appraisal, assert, assumption, attention, build, challenging, Ciccotelli, close, closing, commenced, complaint, confidential, consent, constitute, consummated, consummation, converted, Court, create, cured, customary, Delaware, delivered, demand, devote, DGCL, dispose, District, diverted, document, Dohme, earlier, Eastern, enjoin, entitled, exacerbated, expressly, failure, Finger, foregoing, fourth, frame, iii, incomplete, indirect, injunction, injunctive, intermediate, inventory, Jersey, Kent, Kulish, law, lawsuit, listing, Merck, merged, merger, merit, misleading, mortality, motivate, Nagel, Nasdaq, Overview, par, pendency, Pennsylvania, plaintiff, prevent, proceeding, promptly, properly, Proposal, proposed, recruit, relationship, relief, remedy, removed, repurchase, respond, responding, retention, satisfaction, satisfied, Schedule, seller, shareholder, Sharp, Southern, subsidiary, Superior, tender, tendered, terminated, termination, thereof, timeframe, transaction, transfer, transition, unreasonably, validly, vigorously, vote, waiting, Wang, Whitfield, wholesaler, Wilson, wire, withdrawn, withheld, written, York
Removed:
half, threatened
Financial report summary
?Competition
Geron • FibroGen • Sangamo Therapeutics • Cytokinetics • United Therapeutics • Sanofi • MedAvail • Agios Pharmaceuticals • Keros Therapeutics • CRISPR TherapeuticsRisks
- The pendency of the transaction with Merck could adversely affect our business, financial results and/or operations.
- While the Merger Agreement is in effect, we are subject to restrictions on our business activities.
- In certain instances, the Merger Agreement requires us to pay a termination fee to Merck, which could require us to use available cash that would have otherwise been available for general corporate purposes.
- Lawsuits have been filed against us and other lawsuits may be filed against us and/or Merck challenging the transactions contemplated by the Merger Agreement. An adverse ruling in any such lawsuit may delay or prevent the proposed acquisition from being completed.
- We have incurred, and will continue to incur, direct and indirect costs as a result of the pending transaction with Merck.